Table 2 Efficacy data for chemotherapy and immunotherapy trials that included patients with BRAF-mutant NSCLC

From: BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape

Treatment

Patients, n (BRAF mutation)

Treatment status

Median follow-up, mo

ORR, %

Median PFS, mo

Median OS, mo

Ref

Platinum-based doublet chemotherapya

7 (V600E)

Treatment-naive

13.7

29

4.1

10.8b

6

7 (non-V600E)

13.7

71

8.9

15.2

Platinum-based doublet chemotherapyc

23 (V600E and non-V600E)

Treatment-naive

NA

NA

6.4

18.4

104

Immunotherapyd

12 (V600E)

Treatment-naive and previously treated

5.5

25

3.7

NE

76

10 (non-V600E)

33e

4.1

NE

Immunotherapyf

17 (V600E)

Treatment-naive and previously treated

16.1

24

1.8

8.2

77

18 (non-V600E)

4.1

17.2

Immunotherapyg

26 (V600)

Treatment-naive and previously treated

9.2

26

5.3

22.5

23

18 (non-V600)

35

4.9

12.0

Immunotherapyh

8 (V600E)

Treatment-naive

NA

38

10.5

NA

105

7 (non-V600E)

43

10.8

NA

Immunotherapy as monotherapy or in combinationi

43 (V600E)

Treatment-naive and previously treated

16.2

51.7

10.0

18.5

83

16 (non-V600E)

31.1

8.0

16.0

Immunotherapy-combined chemotherapyj

9 (V600E)

Treatment-naive

NA

56

18.5

NA

82

7 (V600E)

Previously treated

NA

29

1.9

NA

  1. NA not available, NE not estimable, ORR objective response rate, OS overall survival, PD-1 programmed cell death protein 1, PD-L1 programmed death ligand 1, PFS progression-free survival.
  2. aAll patients received platinum-based doublet combination chemotherapy.
  3. bMedian OS was calculated for n = 12 in each group.
  4. cAll patients received platinum-based doublet chemotherapy (most commonly, carboplatin-pemetrexed with or without bevacizumab, but several patients received cisplatin instead of carboplatin and docetaxel or etoposide instead of pemetrexed).
  5. dIncludes nivolumab (n = 11), pembrolizumab (n = 10), and atezolizumab (n = 1).
  6. eORR for non-V600E was calculated out of 9 patients.
  7. fMost patients (94%) in the full study received anti-PD-1 antibodies (nivolumab [n = 466], pembrolizumab [n = 48], other [n = 6]) or anti-PD-L1 antibodies (atezolizumab [n = 19], durvalumab [n = 11], other [n = 1]). The treatment breakdown for specifically the BRAF-mutant cohort was not reported.
  8. gFor the V600 cohort, this includes nivolumab (n = 18), pembrolizumab (n = 6), and other (n = 2). For the non-V600 cohort, this includes nivolumab (n = 16) and pembrolizumab (n = 2).
  9. hPrimarily pembrolizumab either as monotherapy or in conjunction with chemoimmunotherapy for three of the non-V600E patients.
  10. iSpecific immunotherapy treatments were not provided. Of the patients with BRAF-mutant NSCLC (n = 59), 30.5% received immunotherapy monotherapy, 62.7% received immunotherapy plus chemotherapy, and 6.8% received immunotherapy plus anti-angiogenesis.
  11. jSpecific therapies were not specified.
Back to article page